 |
306 Products |  |
1129 Diseases | | 306 Products |
|
4023 Trials |  |
219432 News |  |
| «12...1617181920212223242526...26722673» |
- Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
INVASIVE PNEUMOCOCCAL DISEASE (IPD) AND SEROTYPE DISTRIBUTION AMONG CHILDREN WITH AND WITHOUT COMORBID CONDITIONS IN FINLAND IN 2015 (Exhibition; Board-194) - Apr 14, 2026 - Abstract #ISPPD2026ISPPD_552;
The Finnish national vaccination program has included the 10-valent pneumococcal conjugate vaccine (PCV10) since 2010 and is switching to the 13-valent vaccine (PCV13) during 2025
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
REANALYSING PNEUMOCOCCAL ANTIBODY RESPONSES IN DIAGNOSIS OF PRIMARY ANTIBODY DEFICIENCY IN ADULTS (Exhibition; Board-119) - Apr 14, 2026 - Abstract #ISPPD2026ISPPD_469;
PRP scores were calculated using post-Pneumovax antibody response data from 120 healthy Danish adults between ages of 16-65 years (2)...doi: 10.1007/s10875-025-01915-w 3. https://esid.org/wp-content/uploads/2023/09/ESID-Clin-Crit_omim_orpha_hpo_11_2019fin.pdf
- ||| sunekafusp alpha (ANV600) / Anaveon
Enrollment closed, First-in-human: A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) (clinicaltrials.gov) - Apr 14, 2026
P1/2, N=240, Active, not recruiting, Sponsor: Anaveon AG
https://esid.org/wp-content/uploads/2023/09/ESID-Clin-Crit_omim_orpha_hpo_11_2019fin.pdf Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date: A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) (clinicaltrials.gov) - Apr 14, 2026
P1/2, N=20, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Initiation date: Mar 2026 --> Jun 2026
- || MK-8527 / Merck (MSD)
New P1 trial: A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020) (clinicaltrials.gov) - Apr 14, 2026
P1, N=14, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- ||| ATG-022 / Antengene
Enrollment open: CLINCH-2: A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Apr 14, 2026
P1/2, N=132, Recruiting, Sponsor: Antengene Biologics Limited
Initiation date: Mar 2026 --> Jun 2026 Not yet recruiting --> Recruiting
- || nemtabrutinib (MK-1026) / Merck (MSD)
Enrollment closed: A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (clinicaltrials.gov) - Apr 14, 2026
P1, N=24, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Remicade (infliximab) / J&J
Trial primary completion date: DEVELOP: A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (clinicaltrials.gov) - Apr 14, 2026
P=N/A, N=4970, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
- ||| Welireg (belzutifan) / Merck (MSD)
Enrollment change, Monotherapy: LITESPARK-015: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2? Related Genetic Alterations (MK-6482-015) (clinicaltrials.gov) - Apr 14, 2026
P2, N=322, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting N=170 --> 322
- ||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - Apr 14, 2026
P3, N=2360, Active, not recruiting, Sponsor: Sanofi
N=170 --> 322 Recruiting --> Active, not recruiting | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Oct 2027
- | CDX-1140 / Celldex, Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) (clinicaltrials.gov) - Apr 14, 2026
P1, N=24, Active, not recruiting, Sponsor: Providence Health & Services
Recruiting --> Active, not recruiting | Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Oct 2027 Trial primary completion date: Dec 2025 --> Dec 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
New P2 trial, Mismatch repair, dMMR: NIVO1002024: Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2026
P2, N=30, Active, not recruiting, Sponsor: Blokhin's Russian Cancer Research Center
- || gotistobart (BNT316) / OncoC4, BioNTech
Trial primary completion date, Platinum resistant: PRESERVE-004: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Apr 14, 2026
P2, N=58, Active, not recruiting, Sponsor: OncoC4, Inc.
Trial primary completion date: Dec 2025 --> Dec 2026 Trial primary completion date: Oct 2025 --> Aug 2026
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: Vebrekotuzumab (clinicaltrials.gov) - Apr 14, 2026
P2, N=104, Recruiting, Sponsor: Fudan University
Trial primary completion date: Oct 2025 --> Aug 2026 N=52 --> 104
- |||| enlicitide decanoate (MK-0616) / Merck (MSD), UCB
Trial initiation date: A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) (clinicaltrials.gov) - Apr 14, 2026
P2/3, N=153, Recruiting, Sponsor: Merck Sharp & Dohme LLC
- | ruzasvir (MK-8408) / Atea Pharma
Trial completion date, Trial primary completion date: AT-01B-010: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function (clinicaltrials.gov) - Apr 14, 2026
P1, N=28, Recruiting, Sponsor: Atea Pharmaceuticals, Inc.
N=52 --> 104 Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
- |||||||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P3 trial, IO biomarker: ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC (clinicaltrials.gov) - Apr 14, 2026
P3, N=494, Not yet recruiting, Sponsor: ImmunityBio, Inc.
- ||||| enlicitide decanoate (MK-0616) / Merck (MSD), UCB
Trial initiation date: A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (clinicaltrials.gov) - Apr 14, 2026
P3, N=975, Recruiting, Sponsor: Merck Sharp & Dohme LLC
- | Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Review, Journal: Unresolved questions in the sequencing of systemic therapy for advanced urothelial carcinoma. (Pubmed Central) - Apr 14, 2026
Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026 No abstract available
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Clinical, Journal: Evaluating Random-Access CLIA for Anti-TNF Drug Monitoring: a Comparison with Traditional ELISA. (Pubmed Central) - Apr 14, 2026
The i-TRACK10 analyzer provides a reliable, accurate, and efficient alternative to traditional ELISA kits for therapeutic drug monitoring of anti-TNF agents. Its enhanced automation and performance characteristics support its integration into routine clinical laboratory workflows.
- | Journal, HEOR: Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective. (Pubmed Central) - Apr 14, 2026
Budget impact analysis showed an increase of COP 160,067,748,642 (US$ 39.32 million) (+42.8%). CT+avelumab+BSC had the lowest annual cost, suggesting it is affordable versus EV+PEM and NIV+CT.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Is a Clinical Trial With a Non-Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK. (Pubmed Central) - Apr 14, 2026
In certain scenarios, validation against intrasubject variability may meet the dual objectives of capturing PK variability and confirming sensitivity within the absorption model. Using the final model, we demonstrated BE between adult and pediatric formulations of olaparib in adults and showed minimal food effect on its exposure in pediatrics.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib Promotes Metabolic Reprogramming Through RTK to Inhibit Hepatocellular Carcinoma Proliferation and Metastasis. (Pubmed Central) - Apr 14, 2026
Using the final model, we demonstrated BE between adult and pediatric formulations of olaparib in adults and showed minimal food effect on its exposure in pediatrics. These findings establish that lenvatinib inhibits HCC by regulating lipid metabolism through the PDGF/GFR-MAPK-PLA2G4E axis, expanding the mechanistic understanding of RTK inhibitors and proposing metabolic pathway-targeted combination therapies for HCC.
- | Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Hyperprogression after Anti-Programmed Death-1 Therapy in a Case of Sigmoid Colon Cancer with Lynch Syndrome. (Pubmed Central) - Apr 14, 2026
This case underscores the importance of early response evaluation in ICI-treated MSI-H tumors. Rapid disease progression requires prompt differentiation between HPD and pseudoprogression, emphasizing the necessity of timely therapeutic modification.
- | prednisone / Generic mfg., Noxafil (posaconazole) / Merck (MSD), voriconazole / Generic mfg.
Journal: Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review. (Pubmed Central) - Apr 14, 2026
This report describes a 61-year-old male patient with a history of chronic obstructive pulmonary disease and rheumatoid arthritis who had been receiving long-term treatment with prednisone...The initial diagnosis was pulmonary aspergillosis, and antifungal treatments such as voriconazole, caspofungin and posaconazole were administered successively...For patients with pulmonary aspergillosis undergoing immunosuppressive therapy who fail to respond to standard anti-aspergillosis treatment, the possibility of concurrent mucor infection should be highly suspected. Emphasize the advantages of direct microscopic examination in rapidly identifying pathogen infections, optimizing treatment strategies, and improving prognosis.
- || Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
P4 data, Journal, Adverse events: Post-marketing pharmacovigilance of tedizolid: emerging safety signals. (Pubmed Central) - Apr 14, 2026
Post-marketing data confirm TED's hematologic risks and reveal additional potential hepatic, neuropsychiatric, and gastrointestinal signals. These findings merit further evaluation and prospective studies to clarify clinical significance, establish causality, and optimize monitoring strategies.
- | Journal: Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report (Pubmed Central) - Apr 14, 2026
These findings merit further evaluation and prospective studies to clarify clinical significance, establish causality, and optimize monitoring strategies. First-line conversion therapy with oxaliplatin, fluoropyrimidine, sintilimab (a programmed death-1 inhibitor), and later trastuzumab yielded only transient stabilization followed by clear progression: After six cycles, AFP rose to 1 546.07 ?g/L and target lymph nodes enlarged to 46 mm
- | Prevymis (letermovir) / Merck (MSD)
Journal: Time exploration of initiating letermovir for the prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. (Pubmed Central) - Apr 14, 2026
First-line conversion therapy with oxaliplatin, fluoropyrimidine, sintilimab (a programmed death-1 inhibitor), and later trastuzumab yielded only transient stabilization followed by clear progression: After six cycles, AFP rose to 1 546.07 ?g/L and target lymph nodes enlarged to 46 mm No abstract available
- | Zolinza (vorinostat) / Merck (MSD), Epidaza (chidamide) / Chipscreen, TNG260 / Tango Therap
Journal: Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors. (Pubmed Central) - Apr 14, 2026
Trapoxin A displayed remarkable discrepancies between assays, as it showed fast dissociation kinetics in the biochemical assay, but tight-binding properties in a cellular setting. These findings not only address the previously unexplored dissociation kinetics of two clinically relevant inhibitors, but also underscore the importance of comprehensive kinetic profiling of novel HDAC inhibitors in cellular models.
- | Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Clinical data, Journal: Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. (Pubmed Central) - Apr 14, 2026
The decrease in Tregs at week 3 was observed to predict better PFS. In patients with metastatic NSCLC receiving first-line pembrolizumab with or without chemotherapy, the addition of bronchoscopic cryotherapy was associated with a detectable peripheral immune remodeling and a higher objective response rate, whereas PFS and OS were numerically longer but not statistically different.
- | Remicade (infliximab) / J&J
Journal: Prognostic Utility of Albumin and the C-Reactive Protein-to-Albumin Ratio for Predicting Intravenous Steroid Response in Acute Severe Ulcerative Colitis. (Pubmed Central) - Apr 14, 2026
Among nonresponders, 25% required infliximab rescue therapy, and colectomy occurred in 12.2%...In contrast, day 7 measurements appear to reflect ongoing inflammatory dynamics and treatment evolution rather than true baseline predictors. Serial assessment of these biomarkers may support treatment monitoring and help optimize the timing of rescue therapy.
- | Keytruda (pembrolizumab) / Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal, Monotherapy, Real-world evidence, PD(L)-1 Biomarker, IO biomarker: Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. (Pubmed Central) - Apr 14, 2026
Outcomes were primarily driven by baseline clinical factors, particularly performance status and the degree of PD-L1 expression. Larger cohorts with longer follow-up are warranted to clarify potential differences and assess long-term outcomes.
- | Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: Open Surgical Management of Renal Cell Carcinoma with Infradiaphragmatic Venous Tumor Thrombus (Mayo Levels 0-III): The Epitome of Surgical Self-Reliance in Urology. (Pubmed Central) - Apr 14, 2026
Open surgery remains the cornerstone of curative treatment for RCC with infradiaphragmatic VTT, requiring meticulous preoperative planning and multidisciplinary collaboration at high-volume centers. Integration of perioperative systemic therapies and robotic-assisted approaches holds promise for further improving outcomes in this challenging patient population.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Leveraging Network-Based Transcriptome Analysis from Mouse Tumor Models and Explainable Artificial Intelligence to Advance the Understanding of the Antitumor Activity of Lenvatinib. (Pubmed Central) - Apr 14, 2026
Integration of perioperative systemic therapies and robotic-assisted approaches holds promise for further improving outcomes in this challenging patient population. These network modules exhibit biological functions that are linked to the known targets of lenvatinib in the cancer cells or the tumor microenvironment, highlighting their potential relevance as determinants of drug response.
- | Preclinical, Journal: An In Silico and In Vitro Approach Identified Potential Trypanothione Synthetase Inhibitors with Trypanocidal Activity. (Pubmed Central) - Apr 14, 2026
Therefore, the results encourage the use of these drugs to develop new anti-T. cruzi agents.
- | Noxafil (posaconazole) / Merck (MSD), itraconazole / Generic mfg.
Journal: Refractory Dermatophytosis in a Spitz Dog Successfully Managed with Posaconazole: A Case Report. (Pubmed Central) - Apr 14, 2026
This report documents a case of refractory dermatophytosis in which AFST informed the selection of posaconazole therapy. It highlights the diagnostic challenges of recurrent dermatophytosis, suggests that AFST-guided treatment strategies may help manage infections unresponsive to standard antifungal therapy, and demonstrates that posaconazole is a promising alternative antifungal agent for refractory dermatophytosis in dogs.
- | Review, Journal: Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies. (Pubmed Central) - Apr 14, 2026
Continued research in ICU-specific populations, especially regarding pharmacokinetics in patients on ECMO or CRRT, is urgently needed. In summary, while the therapeutic landscape for carbapenem-resistant Gram-negative infections has evolved substantially, sustained success will rely on a multifaceted strategy combining innovation, precision, and prevention to improve outcomes for the most vulnerable patients.
- | MK-2206 / Merck (MSD)
Journal: Hypoxia synergizes cGAS-STING activation and AKT1 phosphorylation to drive pulmonary inflammation in one-lung ventilation: therapeutic attenuation by RU.521 and MK2206. (Pubmed Central) - Apr 14, 2026
Subsequently, AKT1 modulates the downstream phosphorylation of TBK1, IRF3, and NF-?B, thereby promoting DNA damage-associated inflammation in alveolar epithelial cells. Pharmacologically, both the cGAS inhibitor RU.521 and AKT1 inhibitor MK2206 attenuated cGAS-STING-mediated inflammation and mitigated hypoxia-induced oxidative stress in alveolar epithelia.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Candexch algorithm-enhanced chemometric determination of a novel anti-COVID-19 therapeutics in plasma and paxlovid formulation using advanced multivariate modeling: a sustainability-centered bioanalytical approach. (Pubmed Central) - Apr 14, 2026
Complementary operational and innovation assessments yielded Blue Applicability Grade Index and Violet Innovation Grade Index scores of 90.00 and 80.00, respectively, while the integrated Normalized Quality Score reached 83%. Collectively, the developed platform provides a cost-efficient and environmentally considerate analytical approach suitable for pharmaceutical quality control and preliminary bioanalytical screening in fortified plasma matrices, particularly in laboratories lacking access to advanced chromatographic instrumentation.
- | Piqray (alpelisib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Annexin A3 potentiates lenvatinib resistance in hepatocellular carcinoma through multiple approaches amplified by a positive feedback loop. (Pubmed Central) - Apr 14, 2026
This study reports ANXA3 as a biomarker o predict poor prognosis and lenvatinib resistance in HCC. The combined use of Alpelisib and lenvatinib may serve as a potential therapeutic strategy for lenvatinib-resistant HCC.
- | Journal: Advances in clinical management of acute severe ulcerative colitis (Pubmed Central) - Apr 14, 2026
Previously, guidelines recommended infliximab and cyclosporine as the main salvage therapies; however, recent years have witnessed clinical advances...Among small-molecule Janus kinase inhibitors, tofacitinib as an adjunct to intravenous corticosteroids improves short-term response rates, while upadacitinib shows promise as a salvage therapy when intravenous corticosteroids, conventional or intensified infliximab are ineffective...In addition, exclusive enteral nutrition and hyperbaric oxygen therapy play important roles in the comprehensive management of ASUC by modulating gut microbiota and promoting mucosal healing, respectively. This article reviews the therapeutic outcomes and limitations of these emerging pharmacological agents or regimens in the clinical treatment of ASUC, aiming to provide a reference for optimizing clinical management strategies for ASUC.
- | Tukysa (tucatinib) / Pfizer
Journal: Tucatinib alleviates postmenopausal osteoporosis by suppressing osteoclast differentiation via regulating the DRP1/NFATc1/CTSK signaling pathway. (Pubmed Central) - Apr 14, 2026
By simultaneously modulating of the DRP1/NFATc1 axis and CTSK enzymatic activity, offering a promising dual-action therapeutic strategy for PMOP. Our findings demonstrate that Tucatinib alleviates osteoporotic bone loss by simultaneously modulating the DRP1/NFATc1 axis and CTSK enzymatic activity, offering a promising dual-action therapeutic strategy for PMOP.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, paclitaxel / Generic mfg.
P3 data, Journal, Platinum resistant: Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. (Pubmed Central) - Apr 14, 2026
P3
Our findings demonstrate that Tucatinib alleviates osteoporotic bone loss by simultaneously modulating the DRP1/NFATc1 axis and CTSK enzymatic activity, offering a promising dual-action therapeutic strategy for PMOP. Pembrolizumab plus weekly paclitaxel, with or without bevacizumab, significantly improved progression-free survival and overall survival in participants with platinum-resistant recurrent ovarian cancer who had received one to two previous systemic regimens, supporting this regimen as a new treatment option for this population.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Checkpoint inhibition, Real-world evidence: Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: A real-world study. (Pubmed Central) - Apr 14, 2026
This real-world study supports the possibility of using lenvatinib combined with ICI for the management of patients with unresectable, recurrent, or metastatic HCC, including first-line treatment. Confirmation through a formal clinical trial would provide firmer conclusions.
- ||| intismeran autogene (mRNA-4157) / Merck (MSD), Moderna, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial initiation date: INTerpath-13: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov) - Apr 14, 2026
P2, N=180, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Confirmation through a formal clinical trial would provide firmer conclusions. N=59 --> 180
- |||| Jiataile (sacituzumab tirumotecan) / Merck (MSD)
New P2 trial: Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) (clinicaltrials.gov) - Apr 14, 2026
P2, N=68, Not yet recruiting, Sponsor: National Cancer Centre, Singapore
- ||| opevesostat (MK-5684) / Merck (MSD)
Trial initiation date, Pan tumor: A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (clinicaltrials.gov) - Apr 14, 2026
P2, N=250, Recruiting, Sponsor: Merck Sharp & Dohme LLC
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial suspension, Tumor mutational burden: NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov) - Apr 14, 2026
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
N=59 --> 180 Recruiting --> Suspended
- || Elahere (mirvetuximab soravtansine-gynx) / AbbVie, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Trial primary completion date, Platinum sensitive: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (clinicaltrials.gov) - Apr 14, 2026
P2, N=53, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Suspended Trial completion date: Oct 2028 --> Jan 2031 | Trial primary completion date: Jan 2028 --> Jan 2029
- || methadone / Generic mfg.
Enrollment open, Trial initiation date: AT-01B-013: Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone (clinicaltrials.gov) - Apr 13, 2026
P1, N=32, Recruiting, Sponsor: Atea Pharmaceuticals, Inc.
Trial completion date: Oct 2028 --> Jan 2031 | Trial primary completion date: Jan 2028 --> Jan 2029 Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Jan 2025